Advanced Colorectal Carcinoma Clinical Trial
— IMPACTOfficial title:
Phase 2, Randomized, Double-blind, Placebo-controlled, Multi-Center Study of a Maintenance Therapy With Immunomodulator MGN1703 in Patients With Advanced Colorectal Carcinoma With Disease Control After Initial First-line Therapy
This is a phase 2, randomized, double-blind, multi-center clinical study to evaluate efficacy and safety of a maintenance therapy with the immunomodulator MGN1703 compared to placebo control. The study will be conducted in patients with advanced colorectal carcinoma (AJCC Stage IV) with disease control after first-line standard chemotherapy regimens.
Status | Completed |
Enrollment | 59 |
Est. completion date | March 2013 |
Est. primary completion date | December 2012 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Male and female subjects older than 18 years of age - Histologically confirmed colorectal carcinoma - Radiological confirmation of unresectable advanced colorectal carcinoma (AJCC Stage IV) prior to start of initial first-line therapy - At least one measurable lesion according to RECIST measured within 2 weeks prior to treatment start in case of partial response or stable disease - Prior initial first-line therapy included oral or intravenous fluoropyrimidines/leucovorin,irinotecan or oxaliplatin with or without a standard dose of bevacizumab lasted between 4.5 and 6 months and finished (last day of last cycle) within 2 weeks prior to treatment start (treatment duration with irinotecan or oxaliplatin should not be less than 3 months) - Patients who achieved disease control measured as objective response or disease stabilization after initial first-line therapy - No curative standard therapy is available for the patient after first-line treatment - ECOG performance status 0-1 - Adequate organ function, hemoglobin = 9 g/L, white blood cell count (WBC) = 3.0 x 109/L, absolute neutrophil count = 1.5 x 109/L, platelets > 100 x109/L, aspartate and alanine aminotransferase (AST and ALT) = 2.5 x ULN, bilirubin < 1.5 x ULN, blood creatinine = 1.5 X ULN, prothrombin time (PT) and activated thromboplastin time (aPTT) within normal range - Negative pregnancy test in women with childbearing potential - Expected adequacy of follow-up - Signed informed consent form (ICF) Exclusion Criteria: - More than one line of systemic chemotherapy for metastatic colorectal carcinoma - Tumor progression after initial first-line therapy - Clinically significant concomitant diseases or conditions, which in opinion of the investigator would lead to an unacceptable risk for the subject to participate in the study - Prior or current other malignancy, except adequately treated superficial bladder cancer, basal or squamous cell carcinoma of the skin or other cancer for which the subject has been disease free for more than 3 years - Known central nervous system metastases - Active or uncontrolled infections - Transfusion-dependent anemia - History of autoimmune disease or immune deficiency - Known hypersensitivity to oligonucleotides or excipients of the formulation - Pregnancy and/or nursing - Concurrent chronic systemic immune therapy or immunosuppressant medication, including steroid treatment - Concurrent chemotherapy, hormonal therapy (except hormonal contraception and hormonal replacement therapy for menopausal women), or immunotherapy within the last 2 weeks prior to randomization or during the conduct of the study - Concurrent radiotherapy within the last 6 months prior to randomization or during the conduct of the study - Known HIV seropositivity or active hepatitis B or C infection - Planned major surgery during the study - Participation in another clinical study with other investigational drugs within 30 days prior to the first treatment day - Vaccination within 3 months prior to the first treatment day - Any medical, mental, psychological or psychiatric condition which in opinion of the investigator would not permit the subject to complete the study or understand the patient information - Presence of drug and/or alcohol abuse |
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Austria | Klinik für Innere Medizin I, Abteilung für Klinische Onkologie, Medizinische Universität Wien | Wien | |
Czech Republic | Oncology Clinic, Faculty Hospital Olomouc | Olomouc | |
France | Service de Cancérologie Digestive, Institut de Cancérologie Gustave Roussy | Villejuif | |
Germany | Onkologischer Schwerpunkt am Oskar-Helene-Heim | Berlin | |
Germany | Klinik für Innere Medizin IV, Onkologie/ Hämatologie/ Hämostaseologie, Universitätsklinikum Halle (Saale) | Halle | |
Germany | Kath. Marienkrankenhaus GmbH, Allgemeine Onkologie | Hamburg | |
Germany | Schwerpunktpraxis für Hämatologie und Onkologie | Magdeburg | |
Germany | Klinik für Innere Medizin, Klinik für Hämatologie, Onkologie, Immunologie, Universitätsklinikum Giessen und Marburg GmbH | Marburg | |
Germany | Medizinische Klinik, Abteilung für Onkologie, Hämatologie Immunologie, Rheumatologie und Pulmologie Universität Tübingen, Immuntherapie, Station 65 Med. Klinik Abt. II | Tübingen | |
Russian Federation | Non-state health care institution "Central Clinical Hospital No. 2 named after N.A. Semashko OAO "RZHD" | Moscow | |
Russian Federation | State Institution "Russian Scientific Oncology Center named after N.N. Blokhin RAMN" | Moscow | |
United Kingdom | Mount Vernon Cancer Centre | Northwood | Middlesex |
Lead Sponsor | Collaborator |
---|---|
Mologen AG |
Austria, Czech Republic, France, Germany, Russian Federation, United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Evaluation of median progression-free survival (PFS) in both treatment groups | Measured on accrual time 3 years | No | |
Secondary | Assessment of PFS rate | Measured at landmarks 12, 18 and 24 weeks after treatment start, and afterwards every 6 weeks until treatment stop | No | |
Secondary | Evaluation of median overall survival (OS) | Measured on accrual time 3 years | No | |
Secondary | Assessment of OS proportion in both groups | Measured at landmarks 12, 18 and 24 weeks after treatment start, and afterwards every 6 weeks until treatment stop | No | |
Secondary | Evaluation of overall response rate (ORR) | Measured on accrual time 3 years | No | |
Secondary | Evaluation of duration of response (complete response, partial response, stable disease) as time from initial determination of response to progressive disease measured by RECIST | Measured on accrual time 3 years | No | |
Secondary | Assessment of the dynamic of clinical and laboratory parameters | An average time: participants are followed until progress | No | |
Secondary | Evaluation of immunologic response to MGN1703 | An average time: participants are followed until progress | No | |
Secondary | Assessment of quality of life (QOL) | An average time: participants are followed until progress | No | |
Secondary | Assessment of the safety profile of MGN1703 | An average time: participants are followed until progress | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04582981 -
Fruquintinib and Raltitrexed Versus Fruquintinib Monotherapy in Advanced Colorectal Cancer
|
Phase 2 | |
Active, not recruiting |
NCT04164069 -
Dasatinib for the Prevention of Oxaliplatin-Induced Neuropathy in Patients With Metastatic Gastrointestinal Cancer Receiving FOLFOX Chemotherapy With or Without Bevacizumab
|
Phase 1 | |
Terminated |
NCT05648006 -
First-line Maintenance of OH2 Injection for Advanced Colorectal Cancer
|
Phase 2 | |
Active, not recruiting |
NCT04771715 -
Regorafenib Plus Programmed Cell Death-1 (PD-1) Inhibitors in Patients With Advanced Colorectal Cancer
|
||
Recruiting |
NCT05733000 -
CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid Tumors
|
Phase 2 | |
Active, not recruiting |
NCT02983578 -
Danvatirsen and Durvalumab in Treating Patients With Advanced and Refractory Pancreatic, Non-Small Cell Lung Cancer, and Mismatch Repair Deficient Colorectal Cancer
|
Phase 2 | |
Recruiting |
NCT05967533 -
The Immune Effects of Fermented Wheat Germ Nutritional Supplementation in Patients With Advanced Solid Tumor Cancers Being Treated With Standard of Care Checkpoint Inhibitors
|
Phase 1 | |
Recruiting |
NCT05894694 -
Survival Benefit of Compound Kushen Injection in the Treatment of Advanced Colorectal Cancer
|
Phase 4 | |
Recruiting |
NCT04705818 -
Combining Epigenetic And Immune Therapy to Beat Cancer.
|
Phase 2 | |
Not yet recruiting |
NCT05883683 -
Molecular Study and Precision Medicine for Colorectal Cancer
|
||
Recruiting |
NCT05759923 -
First-in-human Phase I Study to Evaluate Safety, Tolerability and Antineoplastic Activity of OATD-02 in Patients With Selected Advanced and/or Metastatic Solid Tumours
|
Phase 1 | |
Completed |
NCT01277406 -
4SC-201 (Resminostat) in Advanced Colorectal Carcinoma
|
Phase 1/Phase 2 | |
Completed |
NCT04645797 -
A Dose Escalation Study of APR003 in Patients With Advanced Colorectal Cancer (CRC) With Malignant Liver Lesions
|
Phase 1 | |
Recruiting |
NCT05406206 -
Hepatic Arterial Infusion Chemotherapy With Fruquintinib for Colorectal Cancer Liver Metastases As Third-line Therapy
|
Phase 2 | |
Active, not recruiting |
NCT04109924 -
TAS-102, Irinotecan, and Bevacizumab for the Treatment of Pre-treated Metastatic or Unresectable Colorectal Cancer, the TABAsCO Study
|
Phase 2 | |
Recruiting |
NCT04704661 -
Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Patients With Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial
|
Phase 1 | |
Recruiting |
NCT05969860 -
At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer
|
Phase 2 | |
Recruiting |
NCT05200442 -
A Study of VS-6766 and Cetuximab in Patients With Advanced Colorectal Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT00499850 -
Phase I FOLFOX Combination
|
Phase 1 | |
Active, not recruiting |
NCT04535401 -
Testing the Addition of an Anticancer Drug, BAY 1895344, to the Usual Chemotherapy With FOLFIRI in Advanced or Metastatic Cancers of the Stomach and Intestines
|
Phase 1 |